Japanese drugmaker Eisai has announced that the administration of the anticancer agent EZH2 inhibitor Tazverik tablets 200mg ...
Japanese drugmaker Shionogi says it has launched Zurvae capsules 30mg (zuranolone) for the treatment of major depressive disorder (MDD).
US biotech Azitra (NYSE American: AZTR) has secured financing of up to $31.4 million, combining an initial $10.5 million ...
Swiss pharma giant Novartis today announced that it has entered into an agreement with Synnovation Therapeutics to acquire ...
US-German biotech Galimedix Therapeutics has unveiled preclinical data for a next-generation oral Alzheimer’s candidate, ...
Fauna Bio, a specialist in the use of extreme mammal biology and comparative genomics, has announced the designation of a target under its strategic obesity discovery collaboration with Eli Lilly that ...
USA-based immunotherapy specialist SAB Biotherapeutics has announced the closing of an underwritten public offering, ...
Indian drugmaker Glenmark Pharmaceuticals has announced the introduction of two generic products to the US market.
Latin America has never been short of markets that look promising on paper and frustrating in practice. Brazil still belongs ...
US pharma giant Pfizer (NYSE: PFE) has announced positive topline results from the Phase III TALAPRO-3 study. All the news ...
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Icotyde (icotrokinra), an interleukin-23 (IL-23) ...
UK pharma major GSK has announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with PBC.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results